Brokerages Set Carisma Therapeutics, Inc. (NASDAQ:CARM) PT at $4.94

Carisma Therapeutics, Inc. (NASDAQ:CARM) has earned a consensus rating of “Hold” from the seven ratings firms that are covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $4.94.

Several research analysts recently commented on the stock. Robert W. Baird downgraded shares of Carisma Therapeutics from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $10.00 to $1.00 in a report on Thursday, December 12th. HC Wainwright reiterated a “neutral” rating on shares of Carisma Therapeutics in a research report on Monday, December 16th. Evercore ISI reiterated an “in-line” rating and set a $0.70 target price (down from $4.00) on shares of Carisma Therapeutics in a research report on Wednesday, December 11th. Baird R W lowered shares of Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 12th. Finally, D. Boral Capital reiterated a “buy” rating and set a $12.00 target price on shares of Carisma Therapeutics in a research report on Monday, January 13th.

Carisma Therapeutics Stock Down 0.1 %

Carisma Therapeutics stock opened at $0.40 on Tuesday. The company has a market capitalization of $16.72 million, a P/E ratio of -0.26 and a beta of 1.56. The firm’s fifty day simple moving average is $0.46 and its 200-day simple moving average is $0.76. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 1.39. Carisma Therapeutics has a 1-year low of $0.38 and a 1-year high of $2.67.

Hedge Funds Weigh In On Carisma Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Wexford Capital LP grew its holdings in shares of Carisma Therapeutics by 75.5% during the third quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after purchasing an additional 15,000 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Carisma Therapeutics by 11.9% during the fourth quarter. Renaissance Technologies LLC now owns 231,357 shares of the company’s stock worth $97,000 after purchasing an additional 24,600 shares during the last quarter. Finally, Barclays PLC grew its holdings in shares of Carisma Therapeutics by 3,661,933.3% during the third quarter. Barclays PLC now owns 549,305 shares of the company’s stock worth $539,000 after purchasing an additional 549,290 shares during the last quarter. Institutional investors and hedge funds own 44.27% of the company’s stock.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.